Description
P2.18 Responding patients show durable responses to bendamustine in double refractory multiple myeloma patients
- You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart
Article: P2.18 Responding patients show durable responses to bendamustine in double refractory multiple myeloma patients
€3.03
Related products
-
Article: Highlights in digestive oncology
€3.03 Add to cart -
Article: INTRODUCTION
€3.03 Add to cart -
Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer
€3.03 Add to cart -
Article: Calendar of events
€3.03 Add to cart
